medigraphic.com
Órgano Oficial de el Colegio Mexicano de Urología

2002, Número 3

<< Anterior

Bol Col Mex Urol 2002; 17 (3)


Tratamiento medicamentoso oral de la disfunción sexual eréctil

Martínez FL, Fiterre LI

Idioma: Español
Referencias bibliográficas: 144
Paginas: 158-171
Archivo PDF: 100.39 Kb.


RESUMEN

Se revisa el tratamiento medicamentoso oral de la DSE, explicándose la necesidad del logro de drogas más efectivas, haciéndose un recuento histórico de dicha modalidad de tratamiento y aclarándose los problemas actuales que existen en la evaluación de los fármacos para el tratamiento oral de la DSE. Se actualizan las estrategias actuales de tratamiento de dicha afección y finalmente se hace una exposición comentada de los ensayos clínicos realizados hasta el momento, de las drogas erectogénicas clasificadas por grupos farmacológicos (agonistas dopaminérgicos, antagonistas a adrenérgicos, agonistas b adrenérgicos, serotoninérgicos, colinérgicos, inhibidores de la fosfodiesterasa, precursores del óxido nítrico, prostanoides y hormonas).


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Morales A, Heaton JPW, Johnston B, Adans M. Oral and topical treatment of erectil dysfunction. Present and future. Impotence 1995; 22(4): 879-886.

  2. Gomella LG. Editor: Impotence- defining the role of minimally invasive therapy. J Urol 1996; 155: 147.

  3. Eskew A, Nana-Sinkham P, Sabbagh M, Jarow JP. Patient outcome analysis of goal-directed therapy for impotence. J Urol Part 2. 1995; 153: 556. (Abstract) 367A.

  4. Berger RE, Berger DM, Happe-Hartsell CA, Heiman JR. Couples: The “Art” of solving impotence problems. AUA Update series 1988; 7: 154. Lesson 20.

  5. Buffum J. Pharmacosexology: The effects of drugs on sexual function. J Psychoact Drugs 1982; 14: 5-44.

  6. Abel EL. Psychoactive drugs and sex. Plenum Press. New York. 1985.

  7. Rosen RC, Ashton AK. Prosexual drugs: Empirical status of the “New Aphrodisiacs”. Archivos of Sexual Behaviour 1993; 22(6): 521-543.

  8. Rosen RC, Hall E. Sexuality. Random House, New York. 1984.

  9. Flores CA. La impotencia en la Historia. En: Patología y clínica de la impotencia sexual. Ediciones Hormé. Buenos Aires. Editorial Paidos. SAICF 1978: 25-26.

  10. Gallo JS. Impotencia. En: El Folklor Médico de Cuba. Etnología Editorial de Ciencias Sociales. La Habana 1987: 450-458.

  11. Palevitz BA, Lewis R. Erectile dysfunction. Serious research for a serious problem. The Scientist 1998; 12(20): 1, 10-12.

  12. Yat CT, Ying CH, Shin NL, Juei TC. Treatment effect of “Ryu- Wei-Ti-Huang-Wan” (a Chinese herbal prescription) on die sexual performance of male rats with streptozotocin-induced diabetes. Urol Int 1996; 57: 230-234.

  13. Bruhl DE, Leslie CH. Afrodex: Double blind text in impotence. Med Rec Ann 1963; 56: 22.

  14. Margolis R, Leslie CH. Review of studies on a mixture of nux vomica, Yohimbine and methyl testosterone in the treatment of impotence. Curr Ther Res 1966; 8: 280.

  15. I5. Miller WW Jr. Afrodex in the treatment of male impotence: A double blind, cross over study. Curr Ther Res 1968; 10: 354.

  16. Sobotka JJ. An evaluation of Afrodex in the management of male impotence: a double blind crossover study. Curr Iber Res 1969; 11: 87.

  17. Margoliss R, Sangree H, Prieto P, Stein L, Chim S. Clinical studies on the use of Afrodex in the treatment of impotence: statistical summary of 4,000 cases. Curr Ther Res 1969; 9: 213.

  18. Margolis R, Prieto P, Stein L, Chim S. Statistical summary of 10,000 male cases using Afrodex in treatment of impotence. Curr Ther Res 1971; 13: 616.

  19. Nickerson M, Collier B. Drugs inhibiting adrenergic nerves and structures innervated by them. In: The Pharmacological Basis of Therapeutics. 5th ed. Edited by Goodman and Gilman. New York: Mac Millan Publishing Co., Inc, 1975; 26: 533-564.

  20. Morales A, Surridge DHC, Marshall PG, Fenemore J. Nonhormonal pharmacological treatment of organic impotence. J Urol 1982: Vol 128.

  21. Heaton JPW, Adams MA, Morales A. A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative. Int J of Imp Res 1997; 9(3): 115-121.

  22. Heaton JPW. Neural and pharmacological determinants of erection. Int J of Imp Res 1998; 10(2): S34-S39.

  23. Saenz de Tejada I, Cuevas P, Cuevas B, Fernández A, Schroeder J, Shelekin T, Letts G, Garvey D. S-Nitrosylated alpha blockers as potential drugs for the treatment of impotence: Biological activity of NMI-187 and NMI-221. Int J of Imp Res 8. (3).: VII World Meeting on Impotence. (Abstracts). 1996; 103: A-16.

  24. Pfaus JG, Phillips AG. Differential effects of dopamine receptor antagonists in sexual behavior of male rats. Psychopharmacology 1989; 98: 363-368.

  25. Tennent G, Bancroft J, Cass J. The control of deviant sexual behavior by drugs: A double blind controlled study on Benperidol, Chlorpromazine and placebo. Arch Sex Behav 1974; 3: 261-271.

  26. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982; 170: 463-467.

  27. Hyyppa M, Rinne UK, Sonninen V. The activating effect of L-Dopa treatment on sexual functions and its experimental background. Acta Neurol Scand 1970; 46(Suppl 43): 223-224.

  28. Bowers MB, Van Woert M, Davis L. Sexual behavior during L-Dopa treatment for Parkinsonism. Am J Psychiat 1970; 127: 1691-1693.

  29. Angrist B, Gershon B. Clinical effects of amphetamine, and aggression. Comprehen. Psychiat 1976; 17: 715-722.

  30. Brow E, Brown GM, Kofman O, Quarrington B. Sexual function and affect in Parkinson men treated with L-Dopa. Am J Psychiat 1978; 135: 1552-1555.

  31. Benkert O, Crombach G, Kockott G. Effect of L-Dopa on sexually impotent patients. Psychopharmacologia 1972; 23: 91-95.

  32. Jeanty P, Van den Kerchove M, Lowental A, De Bruyne H. Pergolide therapy in Parkinson’s disease. J Neurol 1984; 231: 148-152.

  33. Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B. Hypersensitivity with antiparkinsonian therapy. Clin Neurophamacol 1989; 12: 375-383.

  34. Lal S, Ackman D, Tharundayil JX, Kiely ME, Etienne P. Effects of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Prog Neurol Psychopharmacol Biol Psychiat 1984; 8: 695-699.

  35. Danjou P, Alexandre L, Warot D, Lacomblez L, Puech AJ. Assessment of erectogenic properties of apomorphine and yohimbine in man. Br J Clin Pharmacol 1988; 26: 733-739.

  36. Seagraves RT, Bari M, Seagraves K, Spirmak P. Effect of apomorphine on penile tumescence in men with psychogenic impotence. J Urol 1991.

  37. Lal S, Laryea E, Tharundayil JX, Vasavan NNP, Negrette J, Ackman D, Blundell P, Cardiner R. Apomorphine induced penile tumescence in impotent patients-preliminary findings. Prog Neurol Psychopharmacol Biol Psychiat 1987; 11: 235-242.

  38. Lal S, Tesfaye Y, Tharundayil JX, Thompson TR, Kiely MF, Vasavan NP, Grassino A, Dubrosky B. Apomorphine: Clinical studies on erectile impotence and yawning. Prog Neurol Psychopharmacol Biol Psychiat 1989; 13: 329-339.

  39. Heaton JPW, Morales A, Adams M. Resolution of erectile failure after oral treatment with apomorphine. Urology 1995; 45: 200-203.

  40. Freed E. Increased sexual function with nomifensine. Med J Austral 1983; 1: 551.

  41. Crenshaw TL, Goldberg JP, Stern WC. Pharmacologic modification of psychosexual dysfunction. J Sex Marital Ther 1987; 13: 239-253.

  42. Leonard M, Nickel JC, Morales A. Hyperprolactinemia and impotence: why, when and how to investigate. J Urol 1989; 142: 992-995.

  43. Weiner N. Drogas que bloquean los nervios y receptores adrenérgicos. En: Las bases farmacológicas de la terapéutica. T1. p: 197. Alfred Goodman Gilman, Louis Goodman, y Alfred Gilman. Edición Revolucionaria. Tomada de la sexta edición. 1980.

  44. Scatton B, Dedek J. Antidopaminergic properties of Yohimbine. J Pharmacol Exp Ther 1980; 215: 494-499.

  45. Clark JT, Smith ER, Davidson JM. Enhancement of sexual motivation in male rats by Yohimbine. Science 1984; 224: 847-849.

  46. Clark JT, Smith ER, Davidson JM. Evidence for the modulation of sexual behaviour by alpha-adrenoceptors in male rats. Neuroendocrinology 1985; 41: 36-43.

  47. Strauss EB. Impotence from the psychiatric standpoint. Brit Med J 1950; 1: 697.

  48. Leslie CH, Bruhl DE. An effective anti-impotence agent: statistical, evaluation of 1,000 reported cases. Memphis Mid South Med J 1963; 38: 379.

  49. Walpowitz A, Barnard CN. Impotence after heart transplantation. Letter S Afr Med J 1978; 53: 693.

  50. Bastian HP, Müller J. Yohimbin bei erektiler Dysfunktion. Therapiewoche 1991; 41: 603.

  51. Jacobson FM. Fluoxetine induced sexual dysfunction and an open trial of Yohimbine. J Clin Psych 1992; 53: 119.

  52. Singh AN, Surlock H, Catalan J. Paroxetine induced erectile dysfunction succesfully treated with Yohimbine. J Serotonine Res 1995; 4: 283.

  53. Dean KL, Benson RC, Bilhartz DL, Minich PJ, Furlow WL. A randomized crossover study using Yohimbine and Isoxsuprine versus Pentoxifiline in the management of Vasculogenic impotence. J Urol 1996; 155: 144-146.

  54. Sonda LP, Mazo R, Chancellor MB. The role of Yohimbine for the treatment of erectile impotence. J Sex Marital Ther 1990; 16: 15-22.

  55. Telöken C, Rhoden EL, Sogari P, Dambros M, Vargas SCA. Therapeutic effects of high dose Yohimbine hydrocholide on organic erectile dysfunction. The J of Urol 1998; 159: 122-124.

  56. Morales A, Condra M, Owen JA, Surridge DHC, Fenemore J, Harris C. Is Yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol 1987; 137: 1168-1172.

  57. Reid K, Surridge DH, Morales A. Double-blind trial of Yohimbine in the treatment of psychogenic impotence. Lancet 1987; 2: 42-43.

  58. Riley AJ, Goodman R, Kellet JM, Orr R. Double-blind trial of Yohimbine hydrochloride in the treatment of erection inadequacy. Sex Marital Ther 1989; 4: 17.

  59. Susset JG, Tessier CD, Wincze J, Bansal S, Malhotra C, Schwacha G. Effect of Yohimbine hydrochloride on erectile impotence. A double-blind study. J Urol 1989; 141: 1360-1363.

  60. Mann K, Klinger T, Noe S, Röschke, Müller S, Benkeir O. Effects of Yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction. Arch Sex Behav 1996; 25: 1.

  61. Vogt HJ, Drandl P, Kockott G, Schmitz JR, Wiegand MH, Schadrack H, Glerend M. Double blind, placebo-controlled safety and efficacy trial with Yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Int J of Imp Res 1997; 9(3): 155-161.

  62. Rowland DL, Kallan K, Slob K. Yohimbine, erectile dysfunction, and sexual response in man. Arch Sex Behavior 1997; 26: 49.

  63. Kunelius P, Hakkinen J, Lukkarinen O. Is high dose Yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. Urology 1997; 49(3): 441-444.

  64. Carey MP, Jonhson BT. Effectiveness of Yohimbine in the treatment of erectile disorder: four meta-analytic integrations. Arch Sex Behav 1996; 25: 341.

  65. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. The J of Urology 1998; 159: 433-436.

  66. Morales A, Surridge DHC, Marshall PG. Yohimbine for treatment of impotence in diabetes. New Engl J Med 1981; 305: 1221.

  67. Montorsi F, Strambi LF, Guazzoni G. Effect of Yohimbine- Trazodone in psychogenic impotence: A randomized, double-blind, placebo-controlled study. Urology 1994; 44: 732-736.

  68. Gwinup G. Oral Phentolamine in non-specific erectile insufficiency. Ann Intern Med 1988; 109: 162-163.

  69. Zorgniotti AW. “On demand” oral drugs for erection on impotent men. J Urol 1993; 147: 308A.

  70. Wagner G, Lacy S, Lewis R. Buccal Phentolamine. A pilot trial for male erectile dysfunction at three separate clinics. Int J Imp Res 1994; (Suppl. 1)6: D78.

  71. Becker AJ, Stief CG, Machtens S, Schultheiss D, Hartman U, Truss C. Oral Phentolamine as treatment for erectile dysfunction. J Urol 1998; 159(4): 1214-1215.

  72. García-Reboll L, Mulhall JP, Goldstein I. Drugs for the treatment of impotence. Drugs & Aging 1997; 11(2): 140-151.

  73. Saenz de Tejada I, Ware JC, Blanco R. Pathophysiology of prolonged penile erection associated with Trazodone use. J Urol 1991; 165: 60-63.

  74. Scher M, Krieger J, Jurgens S. Trazodone and priapism. Am J Psychiat 1983; 140: 1362-1363.

  75. Warner MD, Peabody CA, Whiteford HA. Trazodone and Priapism. J Clin Psychiat 1987; 48: 244-245.

  76. Pescadri E, Engelman JC, Davis G. Priapism of the clitoris: A case report following Trazodone use. J Urol 1993; 149: 1557-1559.

  77. Gartrell N. Increased libido in women receiving Trazodone. Am J Psychiat 1988; 143: 781-782.

  78. Sullivan G. Increased libido in three men treated with Trazodone. J Clin Psychiat 1988; 49: 202-203.

  79. Ware JC, Pittard JT, Nadig PW, Morrison JL, Quinn JB. Trazodone: Its effects on nocturnal penile tumescence. Sleep Res 1987; 16: 157.

  80. Ware JC, Rose V, Mc Brayer R. The effects of Nefazodone, Trazodone, Buspirone and placebo on sleep and sleep related penile erections (NPT) in normal subjects. Sleep Res 1991; 20: 91.

  81. Othmer E, Othmer SC. Effect of Buspirone on sexual dysfunction in patients with generalized anxiety disorder. J Clin Psychiat 1987: 48.

  82. Chiang PH, Tsai EM, Chiang CP. The role of Trazodone in the treatment of erectile dysfunction. Kao Hsiung I Hsuen Tsa Chin 1994; 10: 287-294.

  83. Kurt U, Ozkarde SH, Altug U. The efficacy of anti serotoninergic agents in the treatment of erectile dysfunction. J Urol 1994; 152: 407-409.

  84. Meinhardt W, Schmitz PIM, Kropman RF, de la Fuente RB, Nijeholt AABLA, Zwartendljk J. Trazodone, a double blind trial for treatment of erectile dysfunction. Int J of Imp Res 1997; 9(3): 163-165.

  85. Abber JC, Lue TF, Luo J. Priapism, induced by Chlorpromazine and Trazodone: Mechanism of action. J Urol 1987; 137: 1039-1042.

  86. Stevenson RWD, Solyom L. The aphrodisiac effect of Fenfluramine: Two case reports of a possible side effect to the use. J Clin Psychiat 1990; 10: 69-71.

  87. Hsu JH, Shen WW. Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med 1995; 25(2): 191-201.

  88. Mc Lean JD, Forsythe RG, Kapkin IA. Unusual side effects of Clomipramine associated with yawning. Can J Psychiat 1983; 28: 569-570.

  89. Kline MD. Fluoxetine and anorgasmia. Am J Psychiat 1989; 146: 804-805.

  90. Modell JG. Repeated observations of yawning, clitoral engorgement, and orgasm associated with Fluoxetine administration. J Clin Psychopharmacol 1989; 9: 63-65.

  91. Ellison JM. Exercise induced orgasms associated with Fluoxetine treatment of depression. J Clin Psychiat 1996; 57(12): 596-597.

  92. Herman JB, Brotman AW, Pollack MH, Falk WE, Biederman J, Rosenbaum JF. Fluoxetine-induced sexual dysfunction. J Clin Psychiat 1990; 51: 25-27.

  93. Monteiro WO, Noshirvani HF, Marks IM, Lelliot PT. Anorgasmia from Clomipramine in obsessive-compulsive disorder. A controlled trial. Br J Psychiat 1987; 151: 107-112.

  94. Bitran D, Hull EM. Pharmacological analysis of male rat sexual behavior. Neurosci Biobehav Rev 1987; 11: 365-389.

  95. Gross MD. Reversal by bethanecol of sexual dysfunction caused by anticholinergic antidepressants. Am J Psychiat 1982; 139: 1193-1194.

  96. Yager J. Bethanecol chloride can reverse erectile and ejaculatory dysfunction induced by tricyclic antidepressants and Mazindol. Case report. J Clin Psychiat 1986; 47: 210-211.

  97. Sorscher SM, Dilsaver SC. Antidepressant induced sexual dysfunction in men: Due to cholinergic blockade? J Clin Psychopharmacol 1986; 6: 53-55.

  98. Seagraves RT. Reversal by Bethanecol of Imipramine-induced ejaculatory dysfunction. Am J Psychiat 1987; 144: 1243-1244.

  99. Boolel M, Gepi-Attee, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1986; 78: 257-261.

  100. Gingell C, Jardin A, Giuliano FA, Olsson AM, Dinsmore WW, Osterloh IH. The efficacy of Sildenafil (Viagra), a new oral treatment for erectile dysfunction, demonstrated by four different methods in a double-blind placebo-controlled, multinational clinical trial. (Abstract). Eur Urol 1996; 30 (Suppl 2): 353.

  101. Eardley I, Morgan R, Dinsmore WW, Pearson J, Wulff M, Boolell M. Evaluation of the efficacy of Sildenafil (Pfizer UK-92, 480), a new oral treatment for erectile dysfunction (MED) in a double-blind, placebo controlled study. (Abstract). Eur Urol 1996; 30 (Suppl 2): 355.

  102. Buvat JS, Gingell CJ, Jardin A, Olsson AM, Dinsmore WW, Kirkpatrick J. Sildenafil (Viagra), an oral treatment for erectile dysfunction: a 1-year open-label, extension study. (Abstract 793). J Urol 1997; 157 (Suppl): 204.

  103. Derry F, Gardner BP, Glass C, Fraser M, Dinsmore WW, Muirhead G. Sildenafil (Viagra): a double-blind, placebo- controlled, single dose, two-way cross-over study in men with erectile dysfunction caused by traumatic spinal cord injury. (Abstract 702). J Urol 1997; 157 (Suppl): 181.

  104. Lue TF. Sildenafil Study Group: A study of Sildenafil (Viagra), a new oral agent for the treatment of male erectile dysfunction. (Abstract 701). J Urol 1997; 157 (Suppl): 181.

  105. Derry F, Glass C, Dinsmore WW, Fraser M, Gardner BP, Mayton M. Sildenafil (Viagra): an oral treatment for men with erectile dysfunction caused by traumatic spinal cord injury- a 28 day, double-blind, placebo-controlled, parallel-group dose-response study. (Abstract). Neurology 1997; 48 (Suppl 2): 215.

  106. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA, for the Sildenafil Study Group: Oral Sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998; 338(20): 1397-1404.

  107. Marshall KG. Sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998; 339(10): 701.

  108. Steers WD. Sildenafil study group. Meta-analysis of the efficacy of Sildenafil (Viagra) in the treatment of severe erectile dysfunction. (Abstract). J Urol 1998; 159: (Suppl) 238.

  109. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead G, Naylor AM. An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.

  110. Shah PK. Sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998; 339(10): 699.

  111. Saldana MJ, Villaran C, Alhalel B. Sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998; 339(10): 700-700.

  112. Little NLW, Park GT, Patton HM. Sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998; 339(10): 700-700.

  113. Muller JE, Mittleman A, Maclure M, Sherwood JB, Tofler GH. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion. JAMA 1996; 275: 1405-1409.

  114. Drory Y, Shapira I, Fisman EZ, Pines A. Myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol 1995; 75: 835-837.

  115. Morales A, Gingell C, Collins M, Wicker PA, Osterloch IH. Clinical safety of oral Sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impotence Res 1998; 10: 69-74.

  116. Boolell M, Pearson J, Gingell JC, Gepi-Attee S, Wareham K, Price D. Sildenafil study of a novel oral treatment for erectile dysfunction in diabetic men. Diabetic Medicine 1998; 15: 821-825.

  117. Buvat J, Gingell CJ, Jardin A, Olsson AM, Dinsmore WW, Kirkpatrick J, Mayton MC, Orr M, Osterloh IH. The multicentric study group. Sildenafil (ViagraTM), an oral treatment for erectile dysfunction: A 1-year, open label extension study. J Urol 1997; 157(4) (Suppl.): 204. (Abstract) 793.

  118. Gardner BP, Mandeville S, Glass C, Fraser M, Dinsmore WW, Muirhead G, Maytom MC, Orr M. Sildenafil (ViagraTM): A double blind, placebo-controlled, single dose, two-way crossover study in men with erectile dysfunction caused by traumatic spinal cord injury. J Urol 1997; 157. (4). (Suppl): 181 (Abstract) 702.

  119. Prasad K, Elsherif A. Priapism following ingestion of Papaverine tablets. Scandinavian Journal of Urology and Nephrology 1996; 30 (6): 515-516.

  120. Zorgniotti AW, Lizza AF. Effect of large doses of nitric oxide precursor L-arginine on erectile failure. Int J of Imp Res 1994; 6: 33-34.

  121. Ishii N, Watanabe H, Irisawa M, Kikuchi Y, Kawamura S, Suzuki K, Chiba R, Tokiwa M, Shirai M. Studies on male sexual impotence. Report 18 therapeutic trial with prostaglandin E1 for organic impotence. Jpn J Urol 1986; 77: 954-957.

  122. Padma-Nathan H, Hellstrom WJG, Kaiser FE, Labasky RF, Lue TF, Nolten WE, Norwood PC, Peterson CA, Shasigh R, Tam PY, Place VA, Gesundheit N. Treatment of men with erectile dysfunction with transurethral Alprostadil. The New Engl J of Med 1997; 336(1): 1-7.

  123. Sato Y, Horita H, Adachi H, Suzuki N, Tanda H, Kumamoto Y, Tsukamoto T. Effect of oral administration of prostaglandin E1 on erectile dysfunction. British J of Urol 1997; 80(5): 772-775.

  124. O’Carroll R, Bancroft J. Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. Brit J Psychiat 1984; 145: 146.

  125. Nickel JC, Morales A, Condra M, Fenemore J, Surridge DHC. Endocrine dysfunction in impotence: incidence, significance and cost-effective screening. J Urol 1984; 132: 40.

  126. Morales A, Johnston B, Heaton JWP, Clark A. Oral androgens in the treatment of hypogonadal impotent men. J Urol 1994; 152: 1115-1118.

  127. Morales A, Johnston B, Heaton JPW, Lundie M. Testosterone, supplementation for hipogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol 157: 849-854.

  128. 128.Shahidi NT. Androgens and erythropoiesis. New Engl J Med 1973; 289: 72.

  129. Griggs RC, Kingston W, Josefowicz RF, Herr BE, Forbes G, Halliday D. Effect of testosterone on muscle and muscle protein synthesis. J Appl Physiol 1989; 66: 498.

  130. Tenover JS. Androgen administration to aging men. Endocrinol Metab Clin N Amer 1994; 23: 877.

  131. Friedl KE, Hannan CJ, Jones Jr RE, Plymate SR. High- density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metab Clin Exp 1990; 39: 69.

  132. Marin P, Holmäng S, Jönsson L, Sjöström L, Kvist H, Holm G, Lindstedt G, Björntorp P. The effects of testosterone treatment on body composition and metabolism in middle age obese men. Int J Obesity 1993; 16: 991.

  133. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Am Intern Med 1992; 117: 807.

  134. Phillips GB. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994; 14: 701-705.

  135. Vermeulen A. Androgens in the aging male. J Clin Endocr Metab 1991; 73: 221.

  136. Tenover JS. Effect of testosterone supplementation in the aging male. J Clin Endocr Metab 1992; 75: 1092.

  137. Marin P, Holmäng S, Gustafsson C. Androgen treatment of abdominally obese men. Obesity Res 1993; 1: 245.

  138. Franchi F, Luisi M, Kicovic PM. Long term study of testosterone undecanoate in hypogonadal males. Int J Androl 1978; 1: 270.

  139. Behre HM. Prostate volume in testosterone treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrin 1994; 40: 341-349.

  140. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15: 212.

  141. Holmang S. Effect of long term oral testosterone undecanoate treatment on prostate volume and serum prostate specific antigen concentration in eugonadal middle aged men. Prostate 1993; 23: 99-106.

  142. Nankin HR, Lin T, Osterman J. Chronic testosterone cypionate therapy in men with secondary impotence. Fertil Steril 1986; 46: 300.

  143. Mc Clure RD, Oses R, Ernest ML. Hypogonadal impotence treated by transdermal testosterone. Urology 1991; 37: 224.

  144. Morales A, Bain J, Ruijs A, Chapdelaine A, Tremblay RR. Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy. Int J of Imp Res 1996; 8: 95-97.




2020     |     www.medigraphic.com